NDAORALTABLET, CHEWABLE
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
VELPHORO (sucroferric oxyhydroxide) by Fresenius Kabi is phosphate chelating activity [moa]. First approved in 2013.
Drug data last refreshed 17h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELPHORO is an oral chewable phosphate binder containing sucroferric oxyhydroxide, approved in 2013 for managing hyperphosphatemia in patients with chronic kidney disease on dialysis. It works through phosphate chelation, binding dietary phosphate in the gastrointestinal tract to reduce serum phosphate levels. The drug addresses a critical metabolic complication in end-stage renal disease management.
$466MPart D
Peak8.7 years to LOEPeak lifecycle status with strong Part D spending indicates a mature, stable franchise supporting a robust commercial team focused on market maintenance and payer relationships.
Mechanism of Action
Phosphate Chelating Activity
Pharmacologic Class:
Phosphate Binder
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Started Feb 2020
17 enrolled
Peritoneal Dialysis ComplicationHyperphosphatemiaHypoalbuminemia
Why This Matters for Your Career
Worked on VELPHORO at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.